Guidelines for the management of familial hypercholesterolemia

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 12, 2012, Pages 1043-1060

  Harada Shiba, Mariko ^a   Arai, Hidenori ^b   Oikawa, Shinichi ^c   Ohta, Takao ^d   Okada, Tomoo ^e   Okamura, Tomonori ^f   Nohara, Atsushi ^g   Bujo, Hideaki ^h   Yokote, Koutaro ⁱ   Wakatsuki, Akihiko ^j   Ishibashi, Shun ^k   Yamashita, Shizuya ^l,m  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^h CHIBA UNIVERSITY   (Japan)

ⁱ CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k JICHI MEDICAL UNIVERSITY   (Japan)

^l Ministry of Health Labour and Welfare   (Japan)

^m OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Achilles tendon thickness; Coronary artery disease; Diagnosis criteria; LDL cholesterol; LDL receptor

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL;

ACHILLES TENDON; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORNEA CURVATURE; CORONARY ARTERY DISEASE; DIET THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; GENE MUTATION; HEART INFARCTION; HUMAN; JAPAN; KINESIOTHERAPY; LIVER DYSFUNCTION; MYALGIA; RADIOGRAPHY; RISK FACTOR; XANTHOMA;

ACHILLES TENDON; ADOLESCENT; ADULT; AGE FACTORS; AGED; ATHEROSCLEROSIS; CHILD; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FAMILY HEALTH; FEMALE; GUIDELINES AS TOPIC; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; JAPAN; LIPIDS; MALE; MIDDLE AGED; MUTATION; MYOCARDIAL INFARCTION; RISK; XANTHOMATOSIS;

EID: 84871869008     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14621     Document Type: Article

References (85)

1. Mabuchi H, Koizumi J, Shimizu M, Takeda R: Development of coronary heart disease in familial hypercholesterolemia. Circulation, 1989; 79: 225-232.
2. Rees A: Familial hypercholesterolaemia: underdiagnosed and undertreated. Eur Heart J, 2008; 29: 2583-2584.
3. Teramoto T: Status of lipid-lowering therapy prescribed on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res, 2005; 66: 80-95.
4. Mabuchi H: Introduction to Hyperlipidemia. Edited by Asai H, pp35-61, Bunkodo, Tokyo, 2005.
5. Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, Ishibashi S, Shionoiri F, Yamada N, Kita T: Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb, 2004; 11: 146-151.
6. Neil HA, Hawkins MM, Durrington PN, Betteridge DJ, Capps NE, Humphries SE: Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis, 2005; 179: 293-297.
7. Yu W, Nohara A, Higashikata T, Lu H, Inazu A, Mabuchi H: Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis, 2002; 165: 335-342.
8. Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Tada H, Nakanishi C, Mori M, Yamagishi M, Inazu A, Koizumi J: Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis, 2011; 214: 404-407.
9. Ohta N, Yoshida H, Teramoto T, Oikawa S, Saito Y, Yamada N, Shirai K, Ishibashi S, Ishikawa T, Yoshino G, Hirano T: Survey regarding hyperlipidemia treatment in Japan (Survey 1: Complications in hyper-LDL-cholesterolemia and familial hypercholesterolemia patients, as well as survey regarding selected drugs)-LiMAP1-. 37th meeting held by the Japan Atherosclerosis Society, 2005;
10. Maruyama T, Yamashita S, Matsuzawa Y, Bujo H, Takahashi K, Saito Y, Ishibashi S, Ohashi K, Shionoiri F, Gotoda T, Yamada N, Kita T, on behalf of Research Committee on Primary Hyperlipidemia of the Ministry of Health and Welfare of Japan: Mutations in Japanese subjects with primary hyperlipidemia. -Results from the research committee of the Ministry of Health and Welfare of Japan since 1996-. J Atheroscler Thromb, 2004; 11: 131-145.
11. Noguchi T, Katsuda S, Kawashiri MA, Tada H, Nohara A, Inazu A, Yamagishi M, Kobayashi J, Mabuchi H: The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis, 2010; 210: 166-172.
12. Mabuchi H, Higashikata T, Nohara A, Lu H, Yu WX, Nozue T, Noji Y, Katsuda S, Kawashiri MA, Inazu A, Kobayashi J, Koizumi J: Cutoff point separating affected and unaffected familial hypercholesterolemic patients validated by LDL-receptor gene mutants. J Atheroscler Thromb, 2005; 12: 35-40.
13. Yagi K, Hifumi S, Nohara A, Higashikata T, Inazu A, Mizuno KO, Namura M, Ueda K, Kobayashi J, Shimizu M, Mabuchi H: Difference in the risk factors for coronary, renal and other peripheral arteriosclerosis in heterozygous familial hypercholesterolemia. Circ J, 2004; 68: 623-627.
14. Sugisawa T, Okamura T, Makino H, Watanabe M, Kishimoto I, Miyamoto Y, Iwamoto N, Yamamoto A, Yokoyama S, Harada-Shiba M: Defining Patients at Extremely High Risk for Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia. J Atheroscler Thromb, 2012; 19: 369-375.
15. Hirobe K, Matsuzawa Y, Ishikawa K, Tarui S, Yamamoto A, Nambu S, Fujimoto K: Coronary artery disease in heterozygous familial hypercholesterolemia. Atherosclerosis, 1982; 44: 201-210.
16. Yanagi K, Yamashita S, Kihara S, Nakamura T, Nozaki S, Nagai Y, Funahashi T, Kameda-Takemura K, Ueyama Y, Jiao S, Kubo M, Tokunaga K, Matsuzawa Y: Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis, 1997; 132: 43-51.
17. Nakamura T, Kobayashi H, Yanagi K, Nakagawa T, Nishida M, Kihara S, Hiraoka H, Nozaki S, Funahashi T, Yamashita S, Kameda-Takemura K, Matsuzawa Y: Importance of intra-abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia. International journal of obesity and related metabolic disorders, 1997; 21: 580-586.
18. Report in 1986 published by the Specific Disease Primary Hyperlipidemia Survey Research Group, Ministry of Health, Labour and Welfare
19. Rana JS, Jansen AC, Zwinderman AH, Nieuwdorp M, van Aalst-Cohen ES, Jukema JW, Trip MD, Kastelein JJ: Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia. Diabetes Care, 2006, 29: 1125-1127.
20. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, van Lennep HW, Sijbrands EJ, Kastelein JJ: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med, 2004; 256: 482-490.
21. Jensen HK, Hansen PS, Jensen LG, Kristensen MJ, Klausen IC, Kjeldsen M, Lemming L, Bolund L, Gregersen N, Faergeman O: Complexity of molecular genetics of dyslipidemia in a family highly susceptible to ischemic heart disease. Clinical genetics, 1995; 48: 23-28.
22. Holmes DT, Schick BA, Humphries KH, Frohlich J: Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem, 2005; 51: 2067-2073.
23. Nenseter MS, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB, Retterstol K: Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. Atherosclerosis, 2011; 216: 426-432.
24. van Wissen S, Smilde TJ, de Groot E, Hutten BA, Kastelein JJ, Stalenhoef AF: The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. European journal of cardiovascular prevention and rehabilitation, 2003; 10: 451-455.
25. Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y, Yamashita T, Miyamoto Y, Yamamoto A, Tomoike H, Yokoyama S: Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2010; 17: 667-674.
26. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med, 2008; 358: 1431-1443.
27. Yamashita S, Bujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y: Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2008; 15: 292-303.
28. van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagne C, Shi G, Veltri E, Avis HJ, Kastelein JJ: Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol, 2008; 52: 1421- 1429.
29. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS: Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA, 2003; 290: 2271-2276.
30. Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb, 1993; 13: 1291-1298.
31. Okada T, Murata M, Yamauchi K, Harada K: New criteria of normal serum lipid levels in Japanese children: the nationwide study. Pediatr Int, 2002; 44: 596-601.
32. Hattori H NM, Kawamura K, Ishii J, Tsuji M, Iwata F, Yamamura T, Miyake Y, Egashira T, Okada T, Cooper JA, Miller NE, Emi M, Yamamoto A: A flow cytometric procedure to measure functional LDL receptors for diagnosis of familial hypercholesterolemia. Edited by pp357-363, MEDIMOND Inc, Salzburg, 2002.
33. Ohta T, Kiwaki K, Endo F, Umehashi H, Matsuda I: Dyslipidemia in young Japanese children: its relation to familial hypercholesterolemia and familial combined hyperlipidemia. Pediatrics international: official journal of the Japan Pediatric Society, 2002; 44: 602-607.
34. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD: Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics, 2007; 120: e189-214.
35. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J: Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation, 2006; 114: 2710-2738.
36. Mahoney LT, Burns TL, Stanford W, Thompson BH, Witt JD, Rost CA, Lauer RM: Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J Am Coll Cardiol, 1996; 27: 277-284.
37. Davis PH, Dawson JD, Riley WA, Lauer RM: Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation, 2001; 104: 2815-2819.
38. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM: Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med, 1993; 328: 313-318.
39. National Cholesterol Education Program (NCEP): Highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics, 1992; 89: 495-501.
40. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics, 2011; 128 Suppl 5: S213-256.
41. Rask-Nissila L, Jokinen E, Ronnemaa T, Viikari J, Tammi A, Niinikoski H, Seppanen R, Tuominen J, Simell O: Prospective, randomized, infancy-onset trial of the effects of a low-saturated-fat, low-cholesterol diet on serum lipids and lipoproteins before school age: The Special Turku Coronary Risk Factor Intervention Project (STRIP). Circulation, 2000; 102: 1477-1483.
42. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC). The Writing Group for the DISC Collaborative Research Group. JAMA, 1995; 273: 1429-1435.
43. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol, 2002; 40: 2117-2121.
44. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA, 2004; 292: 331-337.
45. Stein EA, Illingworth DR, Kwiterovich PO, Jr., Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA, 1999; 281: 137-144.
46. de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation, 2002; 106: 2231-2237.
47. Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJ, Stein EA: Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol, 2010; 55: 1121-1126.
48. Civeira F: Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis, 2004; 173: 55-68.
49. Khader YS, Rice J, John L, Abueita O: Oral contraceptives use and the risk of myocardial infarction: a metaanalysis. Contraception, 2003; 68: 11-17.
50. Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW: The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol, 2004; 57: 279-286.
51. Wakatsuki A, Sagara Y: Lipoprotein metabolism in postmenopausal and oophorectomized women. Obstet Gynecol, 1995; 85: 523-528.
52. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA, 1995; 273: 199-208.
53. Wakatsuki A, Okatani Y, Ikenoue N: Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. Atherosclerosis, 2000; 150: 103-111.
54. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year followup from the nurses' health study. N Engl J Med, 1991; 325: 756-762.
55. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart dis-ease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 1998; 280: 605-613.
56. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002; 288: 321-333.
57. Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O: Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J, 2008; 29: 2660-2668.
58. Bilheimer DW, Ho YK, Brown MS, Anderson RG, Goldstein JL: Genetics of the low density lipoprotein receptor. Diminished receptor activity in lymphocytes from heterozygotes with familial hypercholesterolemia. J Clin Invest, 1978; 61: 678-696.
59. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 2003; 34: 154-156.
60. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet, 2005; 37: 161-165.
61. Harada-Shiba M, Tajima S, Yokoyama S, Miyake Y, Kojima S, Tsushima M, Kawakami M, Yamamoto A: Siblings with normal LDL receptor activity and severe hypercholesterolemia. Arteriosclerosis and thrombosis, 1992; 12: 1071-1078.
62. Harada-Shiba M, Takagi A, Miyamoto Y, Tsushima M, Ikeda Y, Yokoyama S, Yamamoto A: Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab, 2003; 88: 2541-2547.
63. Hubacek JA, Berge KE, Cohen JC, Hobbs HH: Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Human mutation, 2001; 18: 359-360.
64. Bhattacharyya AK, Connor WE: Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest, 1974; 53: 1033-1043.
65. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science, 2000; 290: 1771-1775.
66. Kim KS, Kubota S, Kuriyama M, Fujiyama J, Bjorkhem I, Eggertsen G, Seyama Y: Identification of new mutations in sterol 27-hydroxylase gene in Japanese patients with cerebrotendinous xanthomatosis (CTX). J Lipid Res, 1994; 35: 1031-1039.
67. Morganroth J, Levy RI, McMahon AE, Gotto AM Jr: Pseudohomozygous type II hyperlipoproteinemia. J Pediatr, 1974; 85: 639-643.
68. Fujita M, Okamoto S, Shirai K, Saito Y, Yoshida S: Pseu-dohomozygous type II hyperlipoproteinemia. Dermatologica, 1991; 182: 94-97.
69. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B: Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol, 1986; 57: 29H-35H
70. Thorogood M, Seed M, De Mott K: Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG, 2009; 116: 478-479.
71. Thompson GR: Recommendations for the use of LDL apheresis. Atherosclerosis, 2008; 198: 247-255.
72. Makino H, Harada-Shiba M: Long-term effect of lowdensity lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial, 2003; 7: 397-401.
73. Thompson GR, Lowenthal R, Myant NB: Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet, 1975; 1: 1208-1211.
74. Yokoyama S, Hayashi R, Satani M, Yamamoto A: Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis, 1985; 5: 613-622.
75. Yamamoto A, Harada-Shiba M, Kawaguchi A, Tsushima M: Apheresis technology for prevention and regression of atherosclerosis. Ther Apher, 2001; 5: 221-225.
76. Mabuchi H, Michishita I, Sakai T, Sakai Y, Watanabe A, Wakasugi T, Takeda R: Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis. Atherosclerosis, 1986; 61: 135-140.
77. Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T: Long-term efficacy of lowdensity lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol, 1998; 82: 1489-1495.
78. Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, et al.: Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet, 1995; 345: 811-816.
79. Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, Stalenhoef AF: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation, 1996; 93: 1826- 1835.
80. Aengevaeren WR, Kroon AA, Stalenhoef AF, Uijen GJ, van der Werf T: Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDLApheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol, 1996; 28: 1696-1704.
81. Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, Retterstol K: Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis, 2006; 189: 451-457.
82. Amundsen AL, Khoury J, Sandset PM, Seljeflot I, Ose L, Tonstad S, Henriksen T, Retterstol K, Iversen PO: Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia. Thromb Res, 2007; 120: 21-27.
83. Beigel Y, Bar J, Cohen M, Hod M: Pregnancy outcome in familial homozygous hypercholesterolemic females treated with long-term plasma exchange. Acta Obstet Gynecol Scad, 1998; 77: 603-608.
84. Naoumova RP, Thompson GR, Soutar AK: Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol, 2004; 15: 413-422.
85. Klingel R, Gohlen B, Schwarting A, Himmelsbach F, Straube R: Differential indication of lipoprotein apheresis during pregnancy. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2003; 7: 359-364